Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH) -- Ignore unavailable to you. Want to Upgrade?

To: JasminW who wrote (45)	3/26/1998 5:36:00 PM
From: Biojunkie	Read Replies (1) \| Respond to of 138

They claim to be in clinical trials with INACTIVIN (PPB2) this year. They just announced yesterday the Hiring of Nanette Onizuka-Handa for the position of Director, Regulatory Affairs. It appears she unexpectedly left Gilead Sciences while working on PREVEON,that company's new Reverse Transcriptase Inhibitor. What does she know about INACTIVIN that we don't? Why did she take such a gamble on this unknown company and technology? I understand that Hollis-Eden has licensing agreements with Edenland and Colthurst Ltd. thereby granting them the worldwide marketing rights to this technology. That information is also found in the company's literature. With a name like Hollis-Eden some people might be able to see the connection.